A correlation between higher PD-L1 expression (on tumor cells and/or immune cells infiltrating the tumor) and likelihood of response to CPIs has been seen in particular in melanoma, NSCLC, and renal cell carcinoma (43–45). The gene discussed is CD274; the disease is renal cell carcinoma.